In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Determined To Update Cosmetics Regs After Claire’s Refuses To Recall Asbestos-Tainted Makeup

Executive Summary

The agency issued a safety alert March 5 advising consumers to avoid three makeup products sold – at least previously – in Claire’s stores, which cater to girls and young women. The situation throws into relief the limitations of the current regulatory framework for cosmetics, which FDA is committed to modernizing while exploring steps to improve oversight using existing tools.

You may also be interested in...



IFRA Implements New Methodology With 49th Amendment To Fragrance Safety Standards

The International Fragrance Association has given its ingredient safety standards a major overhaul based on a new methodology that accounts for aggregate exposure and an updated Quantitative Risk Assessment model for dermal sensitization.

FDA To Hold Public Meeting In February on Cosmetic Talc-Asbestos Test Methods

Recommendations from an FDA-led interagency work group regarding methods for detecting and measuring asbestos in talc and talc-containing cosmetics will be presented at the agency’s planned public meeting in Silver Spring, MD, on 4 February. The recommendations are summarized in the FDA's meeting notice, which follows contentious cosmetic product recalls based on asbestos findings.

FDA Moves Forward With Planned Cosmetic Allergy Survey, Defends Practical Utility, Statistical Power

Based on stakeholder comments, the FDA has made changes to the online questionnaire it plans to use to collect information from 1,000 consumers about adverse events they have experienced and believe were caused by allergens in cosmetic products. The agency remains confident that the pilot study will provide useful insight into cosmetic allergy prevalence in the US.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel